Comera Life Sciences Holdings Inc (NASDAQ:CMRA) shares are trading higher by 46.33% to $2.70 during Wednesday’s after-hours session after the company announced it has entered into a purchase agreement with Arena Business Solutions for up to $15 million of the company’s common stock.
“The line of credit provides the opportunity to invest in our pipeline and proprietary formulation platform, SQore™, which is designed to transform intravenous biologics into subcutaneous versions that patients can self-administer in a single dose,” said Jeffrey Hackman, President, Chief Executive Officer and Chairman of Comera.
“Strengthening our balance sheet will help us achieve our strategic objectives in the near-term, and we are grateful for Arena’s commitment to Comera’s success,” Hackman stated.
See Also: Why Novavax Shares Are Getting Hammered After Moderna, Pfizer And BioNTech News
According to data from Benzinga Pro, Comera Life Sciences has a 52-week high of $15.30 and a 52-week low of $1.11.
